Global Red biotechnology Market 2024-2028

Global Red Biotechnology Market 2024-2028

The red biotechnology market is forecasted to grow by USD 174.56 bn during 2023-2028, accelerating at a CAGR of 6.23% during the forecast period. The report on the red biotechnology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in genomic research, an increase in the prevalence of chronic diseases, and a growing aging population globally.

Technavio's red biotechnology market is segmented as below:

By Product

• Monoclonal antibodies
• Gene therapy
• Polyclonal antibodies
• Cell-based immunotherapy products
• Others

By End-user

• Pharmaceutical and biotechnology companies
• CMOs and CROs
• Academic research institutes

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising stem cell research and therapies as one of the prime reasons driving the red biotechnology market growth during the next few years. Also, the increasing production of biopharmaceuticals and therapeutic proteins and the rising prevalence of bioinformatics and data analytics will lead to sizable demand in the market.

The report on the red biotechnology market covers the following areas:

• Red biotechnology market sizing
• Red biotechnology market forecast
• Red biotechnology market industry analysis

The robust vendor analysis is designed to help clients improve their market position. In line with this, this report provides a detailed analysis of several leading red biotechnology market vendors that include Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Bruker Corp., CRISPR Therapeutics AG, Editas Medicine Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Merck KGaA, Mesoblast Ltd., Moderna Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., STEMCELL Technologies Inc., and Teva Pharmaceutical Industries Ltd.. Also, the red biotechnology market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape and an analysis of the key vendors.

The publisher presents a detailed picture of the market through study, synthesis, and summation of data from multiple sources by analyzing key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.